^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CAT-248

    i
    Other names: CAT-248, CD70 CAR-NK Cell Therapy, CD70-Directed CAR-NK Cells
    Company:
    Catamaran Bio
    Drug class:
    CD70 inhibitor
    Related drugs:
    2years
    Engineering CD70-Directed CAR-NK Cells for the Treatment of Hematological and Solid Malignancies (SITC 2022)
    In functional assays, CD70 knockout CAR-NK cells mediated cytotoxicity against multiple CD70-positive tumor cell lines including AML and RCC both in vitro and in vivo . Conclusions Overall, the results demonstrate the potential for targeting CD70 with CAR-NK cell therapy for the treatment of AML, RCC, and other CD70-positive malignancies while overcoming fratricide issues by engineering with a non-viral transposon delivery system in combination with CRISPR/Cas9 editing.
    IO biomarker
    |
    CD70 (CD70 Molecule) • IL15 (Interleukin 15)
    |
    CD70 expression
    |
    CAT-248
    3years
    Engineering CD70-Directed CAR-NK Cells for the Treatment of Hematological and Solid Malignancies (ASH 2021)
    2008, Clin Cancer Res. 14(23):7763-7772.
    IO biomarker
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD70 (CD70 Molecule) • LAMP1 (Lysosomal Associated Membrane Protein 1)
    |
    CD70 expression • IFNG expression
    |
    CAT-248